Company attributes
Other attributes
Nabriva Therapeutics is a publicly owned clinical stage biopharmaceutical company based in Dublin, Ireland that was founded in 2006 by Rodger Novak. It also has facilities in the US (King of Prussia, PA & San Diego, CA) and Austria (Vienna). It was incorporated as a spin-off from Sandoz GmbH Antibiotics Research Institute (ABRI) in Vienna.The company is engaged in the research and development to treat serious infections, with a focus on the pleuromutilin class of antibiotics.
Nabriva's leading product in its pipeline is Contepo, an investigational epoxide antibiotic with a broad spectrum of bactericidal Gram-negative and Gram-positive activity, including against most contemporary MDR strains. The company gained Contepo through the acquisition of Zavante Therapeutics, its original developer. The FDA has granted Contepo Qualified Infectious Disease Product (QIDP) and Fast Track designations for:
- Complicated urinary tract infections (cUTI)
- Complicated intra-abdominal infections (cIAI)
- Hospital-acquired bacterial pneumonia (HABP) & Ventilator-associated bacterial pneumonia (VABP)
- Acute bacterial skin and skin structure infections (ABSSSI)
As of November 2018, Nabriva completed the Submission of New Drug Application to the FDA.
Another product in Nabriva's pipeline is Lefamulin, which is a semi-synthetic compound that inhibits the synthesis of bacterial protein. It has completed two Phase 3 trials to evaluate the safety and efficacy of Lefamulin (via IV and oral) in the treatment of adults with community-acquired bacterial pneumonia (CABP).
The company is also exploring formulations of Lefamulin for pediatric use and for the treatment of other illnesses such as acute bacterial skin and skin structure infection (ABSSSI), sexually transmitted infections (STIs), ventilator-associated bacterial pneumonia (VABP), osteomyelitis, and prosthetic joint infections.
Nabriva has also completed a Phase 1 clinical trial for BC-7013, a semi-synthetic compound derived from pleuromutilin, for its potential to be developed as a topical treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSIs).
On October 28, 2009 Nabriva Therapeutics completed a venture capital round with $22 million in funding from Nomura Phase 4 Ventures, HBM Partners, Wellcome Trust, GLS Ventures, and Novartis Venture Fund.
On April 7, 2015 Nabriva Therapeutics completed their series B funding round with $120 million in funding from Vivo Capital (lead investor), OrbiMed (lead investor), EcoR1 Capital, Boxer Capital of Tavistock Life Sciences, HBM Partners, Phase4 Partners, Wellcome Trust, GLSV, and Novartis Venture Fund.
On December 21, 2018 Nabriva Therapeutics came to a long term loan agreement for a loan of $75 million from Hercules Capital; and $25 million was funded at the closing of the long term loan deal.
